Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Kansas: - Central Care Cancer Center - Garden City — Garden City, Kansas
- Central Care Cancer Center - Great Bend — Great Bend, Kansas
- HaysMed — Hays, Kansas
- University of Kansas Cancer Center — Kansas City, Kansas
- Lawrence Memorial Hospital — Lawrence, Kansas
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Kansas: - Coffeyville Regional Medical Center — Coffeyville, Kansas
- Central Care Cancer Center - Garden City — Garden City, Kansas
- Saint Catherine Hospital — Garden City, Kansas
- Central Care Cancer Center - Great Bend — Great Bend, Kansas
- HaysMed University of Kansas Health System — Hays, Kansas
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Kansas: - Cotton O'Neil Cancer Center / Stormont Vail Health — Topeka, Kansas
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Kansas: - University of Kansas Cancer Center — Kansas City, Kansas
- The University of Kansas Cancer Center - Olathe — Olathe, Kansas
- University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in Kansas: - Research Site — Fairway, Kansas
Phase 3 Recruiting Academic/Other
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to der…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Sites in Kansas: - The University of Kansas Cancer Center — Westwood, Kansas
Phase 3 Recruiting Industry
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast …
Sponsor: Celcuity Inc
NCT ID: NCT06757634
Sites in Kansas: - The University of Kansas Cancer Center — Westwood, Kansas
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Kansas: - University of Kansas Medical Center (KUMC) — Westwood, Kansas
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this stud…
Sponsor: Gilead Sciences
NCT ID: NCT06926920
Sites in Kansas: - The University of Kansas Hospital — Westwood, Kansas
Phase 2 Recruiting Academic/Other
This is a randomized phase II study to evaluate the pathological complete response (pCR) rate with two neoadjuvant regimens (Docetaxel+Carboplatin+Herceptin/Perjeta and Docetaxel+Herceptin/Perjeta) in HER2 amplified/positive early breast c…
Sponsor: University of Kansas Medical Center
NCT ID: NCT07220135
Sites in Kansas: - The University of Kansas Cancer Center (KUCC) — Fairway, Kansas
- The University of Kansas Cancer Center - Westwood — Kansas City, Kansas
- KUCC - Indian Creek — Overland Park, Kansas
- KUCC - Overland Park — Overland Park, Kansas
- KUCC - Briarcliff — Westwood, Kansas
Phase 2 Recruiting NIH
This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer. The usual approach for patients at increased risk for breast can…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05941520
Sites in Kansas: - University of Kansas Cancer Center — Kansas City, Kansas
Phase 2 Recruiting NIH
This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer. Tamoxifen is a selec…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06195306
Sites in Kansas: - University of Kansas Cancer Center — Kansas City, Kansas
Phase 1, Phase 2 Recruiting Academic/Other
This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
Sponsor: Washington University School of Medicine
NCT ID: NCT06374459
Sites in Kansas: - The University of Kansas Cancer Center — Westwood, Kansas
Phase 1 Recruiting Industry
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to e…
Sponsor: Aktis Oncology, Inc.
NCT ID: NCT07020117
Sites in Kansas: - University of Kansas — Westwood, Kansas
Phase 1 Recruiting NIH
Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells fro…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04222413
Sites in Kansas: - University of Kansas — Fairway, Kansas
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Kansas: - Central Care Cancer Center - Garden City — Garden City, Kansas
- Central Care Cancer Center - Great Bend — Great Bend, Kansas
- Veteran Administration Eastern Kansas Healthcare — Leavenworth, Kansas
- Mercy Hospital Pittsburg — Pittsburg, Kansas
- Cotton O'Neil Cancer Center / Stormont Vail Health — Topeka, Kansas
NA Recruiting Network
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using marke…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03723928
Sites in Kansas: - Central Care Cancer Center - Garden City — Garden City, Kansas
- Central Care Cancer Center - Great Bend — Great Bend, Kansas
- HaysMed University of Kansas Health System — Hays, Kansas
- Lawrence Memorial Hospital — Lawrence, Kansas
- Kansas Institute of Medicine Cancer and Blood Center — Lenexa, Kansas
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Kansas: - HaysMed — Hays, Kansas
- Lawrence Memorial Hospital — Lawrence, Kansas
- The University of Kansas Cancer Center - Olathe — Olathe, Kansas
- University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
- University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
Recruiting Industry
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Pa…
Sponsor: Exact Sciences Corporation
NCT ID: NCT06401421
Sites in Kansas: - University of Kansas Cancer Center — Westwood, Kansas
Recruiting Academic/Other
The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.
Sponsor: Priyanka Sharma
NCT ID: NCT06603597
Sites in Kansas: - KUCC - Indian Creek — Overland Park, Kansas
- KUCC - Overland Park — Overland Park, Kansas
- KUCC - Briarcliff — Westwood, Kansas
- KUCC - Olathe — Westwood, Kansas
- The University of Kansas Cancer Center — Westwood, Kansas
NA Recruiting Academic/Other
This phase II study evaluates SABR as non-operative treatment for women aged 65+ with ER-positive, HER2-negative breast cancer ≤5 cm and no lymph node involvement. Eligible patients, including those previously on endocrine therapy, receive…
Sponsor: University of Kansas Medical Center
NCT ID: NCT07242118
Sites in Kansas: - University of Kansas Medical Center — Kansas City, Kansas
- University of Kansas Medical Center — Kansas City, Kansas